IGM Biosciences, Inc. (IGMS)

Au 14, 2025 - IGMS was delisted (reason: acquired by Concentra Biosciences)

1.270

-0.030 (-2.31%)

Inactive · Last trade price on Aug 13, 2025

Revenue by Product

Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Engineered Immunoglobulin M Antibodies	2.13M	Log In
Engineered Immunoglobulin M Antibodies Growth	99.25%	Log In

Revenue by Geography

Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
United States	2.13M	Log In
United States Growth	99.25%	Log In